References
- 1. A. E. Raizner, Coenzyme Q10, Methodist Debakey Cardiovasc. J. 15(3) (2019) 185–191; https://doi.org/10.14797/mdcj-15-3-185
- 2. T. Hidaka, K. Fujii, I. Funahashi, N. Fukutomi and K. Hosoe, Safety assessment of coenzyme Q10 (CoQ10), Biofactors 32(1–4) (2008) 199–208; https://doi.org/10.1002/biof.5520320124
- 3. B. A. Taylor, Does coenzyme Q10 supplementation mitigate statin-associated muscle symptoms? Pharmacological and methodological considerations, Am. J. Cardiovasc. Drugs 18(2) (2018) 75–82; https://doi.org/10.1007/s40256-017-0251-2
- 4. K. H. Bhandari, M. Newa, J. A. Kim, B. K. Yoo, J. S. Woo, W. S. Lyoo, H. T. Lim, H. G. Choi and C. S. Yong, Preparation, characterization and evaluation of coenzyme Q10 binary solid dispersions for enhanced solubility and dissolution, Biol. Pharm. Bull. 30(6) (2007) 1171–1176; https://doi.org/10.1248/bpb.30.1171
- 5. K. Westesen, Novel lipid-based colloidal dispersions as potential drug administration systems – expectations and reality, Colloid Polym. Sci. 278(7) (2000) 608–618; https://doi.org/10.1007/s003969900257
- 6. S. Xia, S. Xu and X. Zhang, Optimization in the preparation of coenzyme Q10 nanoliposomes, J. Agric. Food Chem. 54(17) (2006) 6358–6366; https://doi.org/10.1021/jf060405o
- 7. J. Garrido-Maraver, M. D. Cordero, M. Oropesa-Ávila, A. F. Vega, M. de la Mata, A. Delgado Pavón, M. de Miguel, C. Pérez Calero, M. Villanueva Paz, D. Cotán and J. A. Sánchez-Alcázar, Coenzyme q10 therapy, Mol. Syndromol. 5(3–4) (2014) 187–197; https://doi.org/10.1159/000360101
- 8. D. L. Hansen, D. Tulinius and E. H. Hansen, Adolescents’ struggles with swallowing tablets: barriers, strategies and learning, Pharm. World Sci. 30(1) (2008) 65–69; https://doi.org/10.1007/s11096-007-9142-y
- 9. R. Matsui, O. Ueda, S. Uchida and N. Namiki, Transdermal absorption of natural progesterone from alcoholic gel formulations with hydrophilic surfactant, Drug Dev. Ind. Pharm. 41(6) (2015) 1026–1029; https://doi.org/10.3109/03639045.2014.925915
- 10. C. Cecchi and P. L. Canonico, Pharmaceutical formulations and adherence to pharmacological treatment in psychiatry: the example of oral disintegrating tablet of olanzapine, Riv. Psichiatr. 47(1) (2012) 30–39; https://doi.org/10.1708/1034.11289
- 11. H. Ascher-Svanum, N. M. Furiak, A. H. Lawson, T. M. Klein, L. J. Smolen, R. R. Conley and S. D. Culler, Cost-effectiveness of several atypical antipsychotics in orally disintegrating tablets compared with standard oral tablets in the treatment of schizophrenia in the United States, J. Med. Econ. 15(3) (2012) 531–547; https://doi.org/10.3111/13696998.2012.662923
- 12. N. Namiki, Clinical functionality required for orally disintegrating tablets selected as the next generation type, Yakugaku Zasshi 135(2) (2015) 237–243; https://doi.org/10.1248/yakushi.14-00228-3
- 13. S. Paul, L. J. Taylor, B. Murphy, J Krzyzaniak, N. Dawson, M. P. Mullarney, P. Meenan and C. C. Sun, Mechanism and kinetics of punch sticking of pharmaceuticals, J. Pharm. Sci. 106(1) (2016) 151–158; https://doi.org/10.1016/j.xphs.2016.07.015
- 14. F. Jin and A. Tatavarti, Tabletability assessment of conventional formulations containing vitamin E tocopheryl polyethylene glycol succinate, Int. J. Pharm. 389(1–2) (2010) 58–65; https://doi.org/10.1016/j.ijpharm.2010.01.017
- 15. Y. Ikematsu, S. Uchida and N. Namiki, Preparation and evaluation of orally disintegrating tablets containing vitamin E as a model fat-soluble drug, Chem. Pharm. Bull. 63(3) (2015) 156–163; https://doi.org/10.1248/cpb.c14-00598
- 16. N. M. Zaki, Strategies for oral delivery and mitochondrial targeting of CoQ10, Drug Deliv. 23(6) (2016) 1868–1881; https://doi.org/10.3109/10717544.2014.993747
- 17. A. Martucci, D. Reurean-Pintilei and A. Manole, Bioavailability and sustained plasma concentrations of CoQ10 in healthy volunteers by a novel oral timed-release preparation, Nutrients 11(3) (2019) Article ID 527 (13 pages); https://doi.org/10.3390/nu11030527
- 18. M. Davis and G. Walker, Recent strategies in spray drying for the enhanced bioavailability of poorly water-soluble drugs, J. Control. Release 269 (2018) 110–127; https://doi.org/10.1016/j.jconrel.2017.11.005
- 19. T. Niwa and K. Danjo, Design of self-dispersible dry nanosuspension through wet milling and spray freeze-drying for poorly water-soluble drugs, Eur. J. Pharm. Sci. 50(3–4) (2013) 272–281; https://doi.org/10.1016/j.ejps.2013.07.011
- 20. M. Kidokoro, Y. Haramiishi, S. Sagasaki, T. Shimizu and Y. Yamamoto, Application of fluidized hot-melt granulation (FHMG) for the preparation of granules for tableting; properties of granules and tablets prepared by FHMG, Drug Dev. Ind. Pharm. 28(1) (2002) 67–76; https://doi.org/10.1081/ddc-120001487
- 21. Y. Takashima, H. Yuasa, Y. Kanaya, I. Nomura and K. Shinozawa, Reduction of tablet coloration at tableting for oily medicine (tocopheryl nicotinate), Int. J. Pharm. 187(1) (1999) 125–135; https://doi.org/10.1016/s0378-5173(99)00179-9
- 22. Y. Kato and M. Takeno, Improvement of content uniformity of d-alpha-tocopheryl acetate as an oily drug in granules by emulsification, Drug Dev. Ind. Pharm. 32(5) (2006) 617–621; https://doi.org/10.1080/03639040500529036
- 23. T. Koseki, H. Onishi, Y. Takahashi, M. Uchida and Y. Machida, Development of novel fast-disintegrating tablets by direct compression using sucrose stearic acid ester as a disintegration-accelerating agent, Chem. Pharm. Bull. 56(10) (2008) 1384–1388; https://doi.org/10.1248/cpb.56.1384
- 24. Food and Drug Administration, Center for Drug Evaluation and Research (CDER), “Guidance for Industry: Orally Disintegrating Tablets,” U.S. Department of Health and Human Services, U.S.A., December 2008; https://www.fda.gov/media/70877/download last access date March 31, 2022.
- 25. T. Sakamoto, S. Kachi, S. Nakamura and H. Yuasa, Potential use of magnesium oxide as an excipient to maintain the hardness of orally disintegrating tablets during unpackaged storage, Chem. Pharm. Bull. 67(3) (2019) 284–288; https://doi.org/10.1248/cpb.c18-00588
- 26. K. Hori, N. Yoshida, T. Okumura, Y. Okamura and J. Kawakami, Method for the evaluation of the stability and usability after opening packages of orally disintegrating tablets: case of amlodipine besilate products, Yakugaku Zasshi 130(8), (2010) 1029–1040; https://doi.org/10.1248/yakushi.130.1029
- 27. S. M. Wong, I. W. Kellaway and S. Murdan, Enhancement of the dissolution rate and oral absorption of a poorly water soluble drug by formation of surfactant-containing microparticles, Int. J. Pharm. 317(1) (2006) 61–68; https://doi.org/10.1016/j.ijpharm.2006.03.001
- 28. K. Terao, D. Nakata, H. Fukumi, G. Schmid, H. Arima, F. Hirayama and K. Uekama, Enhancement of oral bioavailability of coenzyme Q10 by complexation with γ-cyclodextrin in healthy adults, Nutrition Res. 26(10) (2006) 503–508; https://doi.org/10.1016/j.nutres.2006.08.004
- 29. B. Abdulwahab, S. Ranjita, D. Michael and H. M. Rainer, Coenzyme Q10 oral bioavailability: effect of formulation type, J. Pharm. Investig. 43(6) (2013) 431–451; https://doi.org/10.1007/s40005-013-0101-4
- 30. J. Hatanaka, Y. Kimura, Z. Lai-Fu, S. Onoue, S. Yamada, Physicochemical and pharmacokinetic characterization of water-soluble Coenzyme Q(10) formulations, Int. J. Pharm. 363(1–2) (2008) 112–117; https://doi.org/10.1016/j.ijpharm.2008.07.019
- 31. C. J. Pastor-Maldonado, J. M. Suárez-Rivero, S. Povea-Cabello, M. Álvarez-Córdoba, I. Villalón-García, M. Munuera-Cabeza, A. Suárez-Carrillo, M. Talaverón-Rey and J. A. Sánchez-Alcázar, Coenzyme Q(10): Novel formulations and medical trends, Int. J. Mol. Sci. 21(22) (2020) Article ID 8432 (23 pages); https://doi.org/10.3390/ijms21228432